FDA Greenlights BMS, J&J CAR-T Therapies for Earlier Multiple Myeloma Treatment

The approvals, third line for BMS and 2seventy Bio’s Abecma and second line for J&J and Legend Biotech’s Carvykti, represent a new class of therapy for these blood cancer patients.